Oncology Pharma Inc.

ONPH

US68235J2015

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 11:36:25 2024-05-02 am EDT			5-day change	1st Jan Change
0.0001 ^USD	0.00%		+900.00%	-50.00%

2021	NanoSmart Pharmaceuticals, Inc. announced that it has received funding from Oncology Pharma Inc.	CI
2021	Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy	CI

Oncology Pharma Inc. announced that it expects to receive $38.4 million in funding from SCP Partners

December 19, 2019

Oncology Pharma Inc. (OTCPK:ONPH) announced that it has entered into a letter of intent for gross proceeds of $38,400,000 with SCP Partners on December 20, 2019. The transaction is subject to a 90 day due diligence period.

Latest news about Oncology Pharma Inc.

NanoSmart Pharmaceuticals, Inc. announced that it has received funding from Oncology Pharma Inc.	21-03-30	CI
Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy	21-03-10	CI
Oncology Pharma Inc. Moves to Fund Lead Drug Formulation & IND-Enabling Studies	21-03-04	CI
Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent	21-02-26	CI
Oncology Pharma Extends Licensing Agreement with Nanosmart Pharmaceuticals, Inc. for Veterinary Oncology	21-02-22	CI
Oncology Pharma Inc. Announces Henry Smith as New Chairman to Its Scientific Advisory Board	21-02-16	CI
Oncology Pharma Renews Licensing Agreement with Ribera Solutions LLC for Its Connect2med Clinical Trials Platform	21-02-09	CI
Oncology Pharma Announces the Appointment of James Smith as New Chief Financial Officer	21-01-28	CI
Oncology Pharma Inc. cancelled the acquisition of acquire 50% stake in Diagnomics, Inc.	20-12-10	CI
Oncology Pharma and Kalos Therapeutics Expand Licensing Agreement for Exploring Kalos's Anti-Cancer Lead Drug in Treating Covid-19	20-04-06	CI
Oncology Pharma Inc. announced that it expects to receive $38.4 million in funding from SCP Partners	19-12-19	CI
Oncology Pharma Inc. signed a Letter of Intent to acquire 50% stake in Diagnomics, Inc.	19-12-10	CI
Oncology Pharma, Inc. Appoints Dr. Vijay Mahant as the Chief Scientific Officer and Chief Operating Officer	19-10-15	CI
Oncology Pharma Elects Stefan Gruenwald to Its Board of Directors	19-10-08	CI
Oncology Pharma Inc. Appoints Stefan Gruenwald as an Advisor on its Advisory Board	19-07-15	CI
SourcingLink.net, Inc. has Changed its Name to Oncology Pharma Inc	19-06-13	CI
SourcingLink.net Inc. Signs a Letter of Intent with NanoSmart Pharmaceuticals, Inc. for a Licensee and Co-Development Collaboration of NanoSmart's Proprietary Targeted Drug Delivery System for Cancer Drugs	19-02-26	CI
SourcingLink.net to Leverage Pharmacogenomics in Oncology Therapy Development and Clinical Trial Program	19-02-05	CI
SourcingLink.net Inc. cancelled the acquisition of 11 additional lithium claims located on CYR south property in Quebec Canada.	18-04-09	CI
SourcingLink.net Inc. Provides Update on the Lac Fire Lithium Property and Completion of 43-101 Compliant Report with Recommended Work Program	18-03-29	CI
SourcingLink.net Inc. Announces Completion of Phase I Surface Exploration on the Lac Fire Lithium Property in James Bay, Quebec	18-01-25	CI
SourcingLink.net, Inc. to Purchase 11 Lithium Claims Located on the CYR South Property in Quebec, Canada	17-04-10	CI
SourcingLink.net Inc. agreed to acquire 11 additional lithium claims located on CYR south property in Quebec Canada.	17-04-09	CI
SourcingLink.net Inc. Provides an Information Update on the Lac Fire Lithium Property	16-06-29	CI
SourcingLink.net Acquires 8 New Lithium-Tantalum Claims in James Bay, Quebec, Canada	16-04-01	CI

Chart Oncology Pharma Inc.

Duration

Period

More charts

Company Profile

Oncology Pharma, Inc. is an oncology company. The Company is focused on licensing, developing, manufacturing and commercializing therapeutics. The Companyâs research, development, and commercialization of therapeutic drugs and medical devices designed for the treatment of many types of cancers. The Company offers a portfolio, such as Nanosmart Pharmaceuticals Inc. (Nanosmart Pharmaceuticals). The Companyâs NanoSmart platform technology is a human-derived, antinuclear antibody (ANA) that targets areas of necrosis present in solid tumors. Its anti-cancer drugs in combination with medications, for treating a variety of cancers, such as breast, ovarian, lung, bladder, Kaposi's sarcoma, lymphoma and acute lymphocytic leukemia is doxorubicin. Its portfolio also includes Connect2Med, Sybleu, Inc. and Regen.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ONCOLOGY PHARMA INC.	-50.00%	3.87K
ELI LILLY AND COMPANY	+29.68%	699B
NOVO NORDISK A/S	+25.07%	571B
JOHNSON & JOHNSON	-4.35%	364B
MERCK & CO., INC.	+17.65%	326B
ABBVIE INC.	+3.77%	286B
ASTRAZENECA PLC	+14.68%	236B
NOVARTIS AG	+4.71%	198B
ROCHE HOLDING AG	-12.43%	194B
PFIZER, INC.	-3.79%	154B

Other Pharmaceuticals